Hatemi, G. Et Al. 2021. Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.39, no.5 .

Hatemi, G., Mahr, A., Takeno, M., Kim, D. Y., Saadoun, D., DİRESKENELİ, R. H., ... Melikoglu, M.(2021). Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.39, no.5.

Hatemi, G. Et Al. "Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial," CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.39, no.5, 2021

Hatemi, G. Et Al. "Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial." CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.39, no.5, 2021

Hatemi, G. Et Al. (2021) . "Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial." CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , vol.39, no.5.

@article{article, author={G. Hatemi Et Al. }, title={Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial}, journal={CLINICAL AND EXPERIMENTAL RHEUMATOLOGY}, year=2021}